To take the field of obesity and diabetes therapeutics beyond the proven benefits of GLP-1 analogue therapy, investigators have considered the use of GLP-1 in combination with other gut hormones that may bring complementary benefits. The gene discussed is GLP1R; the disease is obesity due to melanocortin 4 receptor deficiency.